Clinical Study
Absorption and Elimination of Oat Avenanthramides in Humans after Acute Consumption of Oat Cookies
Table 3
Pharmacokinetic properties of AVAs.
| | Cmax (ng/ml) | Tmax (h) | T1/2 (h) | | H-AVA | L-AVA | H-AVA | L-AVA | H-AVA | L-AVA |
| AVA-A | 8.39 ± 4.2c | 1.98 ± 1.3 | 2.50 ± 1.2 | 1.80 ± 1.3 | 2.16 ± 0.6b | 2.44 ± 0.8 | AVA-B | 8.44 ± 2.3c | 2.43 ± 1.1 | 2.04 ± 0.9 | 1.50 ± 1.5 | 4.23 ± 0.8ac | 4.60 ± 2.7 | AVA-C | 4.26 ± 2.0ab | 1.33 ± 0.7 | 2.29 ± 1.0 | 1.32 ± 1.0 | 2.71 ± 1.2b | 2.87 ± 1.4 |
|
|
versus H-AVA; a versus AVA-A within H-AVA or L-AVA group; b versus AVA-B within H-AVA or L-AVA group; c versus AVA-C within H-AVA or L-AVA group.
|